Catalog No.
YHJ02201
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Phe1479-Pro1729
Predicted molecular weight
31.84 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q5S007
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Dardarin, Leucine-rich repeat serine/threonine-protein kinase 2, PARK8, LRRK2
Neuropathological examination of 12 cases of familial Parkinson's disease with LRRK2 I2020T mutation including tau and TDP-43 pathology., PMID:40488901
A new LRRK2 variant in a family with Parkinson's disease affects binding to RAB8A., PMID:40483312
Variants in Lrrk2 and Snca deficiency do not alter the course of primary encephalitis due to neurotropic reovirus T3D in newborn mice., PMID:40471880
Type II kinase inhibitors that target Parkinson's disease-associated LRRK2., PMID:40465731
The Role of Kinases in Neurodegenerative Diseases: From Pathogenesis to Treatment., PMID:40464332
Proteome-wide Ligand and Target Discovery by Using β-Nitrostyrene Electrophiles: Supporting Targeted Protein Degradation., PMID:40464197
[Study on mechanism of naringin in alleviating cerebral ischemia/reperfusion injury based on DRP1/LRRK2/MCU axis]., PMID:40461204
LRRK2-mediated mitochondrial dysfunction in Parkinson's disease., PMID:40440058
Leucine-rich repeat kinase 2 biomarkers for Parkinson's disease., PMID:40437812
LRRK2 interactions with microtubules are independent of LRRK2-mediated Rab phosphorylation., PMID:40425780
Active Learning-Guided Hit Optimization for the Leucine-Rich Repeat Kinase 2 WDR Domain Based on In Silico Ligand-Binding Affinities., PMID:40415386
Protective Effect of the LRRK2 Kinase Inhibition in Human Fibroblasts Bearing the Genetic Variant GBA1 K198E: Implications for Parkinson's Disease., PMID:40397198
Inflammation and IL-4 regulate Parkinson's and Crohn's disease associated kinase LRRK2., PMID:40394349
Autophagy Process in Parkinson's Disease Depends on Mutations in the GBA1 and LRRK2 Genes., PMID:40388077
PF-06447475 Molecule Attenuates the Neuropathology of Familial Alzheimer's and Coexistent Parkinson's Disease Markers in PSEN1 I416T Dopaminergic-like Neurons., PMID:40363838
Astrocytes carrying LRRK2 G2019S exhibit increased levels of clusterin chaperone via miR-22-5p and reduced ability to take up α-synuclein fibrils., PMID:40355981
Macrophages in the dCLN are required for α-synuclein proteostasis in A53T PD model mice., PMID:40355037
Molecular and spatial transcriptomic classification of midbrain dopamine neurons and their alterations in a LRRK2G2019S model of Parkinson's disease., PMID:40353820
Discovery of a Chiral 2,4-Substituted Pyrrolo[2,3-d]pyrimidine as a Potent, Selective, and Orally Bioavailable LRRK2 Inhibitor., PMID:40353293
Therapeutic Targeting of Autosomal Parkinson's Disease by Modulation of Leucine-Rich Repeat Kinase 2 (LRRK2) Protein., PMID:40345365
Risk of colorectal cancer in Parkinson's disease: a systematic review and meta-analysis of 11 million participants., PMID:40340810
Dopamine D2 receptor upregulation in dorsal striatum in the LRRK2-R1441C rat model of early Parkinson's disease revealed by in vivo PET imaging., PMID:40335575
Environmental Factors Exacerbate Parkinsonian Phenotypes in an Asian-Specific Knock-In LRRK2 Risk Variant in Mice., PMID:40332013
Emergent glutamate & dopamine dysfunction in VPS35(D620N) knock-in mice and rapid reversal by LRRK2 inhibition., PMID:40319043
Widespread distribution of α-synuclein oligomers in LRRK2-related Parkinson's disease., PMID:40314842
Abundant non-inclusion α-synuclein pathology in Lewy body-negative LRRK2-mutant cases., PMID:40314782
Impact of LRRK2 and GBA variants on orthostatic hypotension in patients with Parkinson's disease., PMID:40314780
The Multifaceted Role of LRRK2 in Parkinson's Disease., PMID:40309866
IC100 blocks inflammasome activation induced by α-synuclein aggregates and ASC specks., PMID:40280940
Lysosomal TPC2 channels disrupt Ca2+ entry and dopaminergic function in models of LRRK2-Parkinson's disease., PMID:40279672
Environmental exposures and familial background alter the induction of neuropathology and inflammation after SARS-CoV-2 infection., PMID:40268936
Actinomyces viscosus promotes neuroprotection in C. elegans models of Parkinson's disease., PMID:40258426
Parkinson's Disease: The Neurodegenerative Enigma Under the "Undercurrent" of Endoplasmic Reticulum Stress., PMID:40244210
The Leucine-Rich Repeat Kinase 2 Variant LRRK2G2019S Up-Regulates L-Type (CaV1.3) Calcium Channel via the CaVβ3 Subunit: Possible Role in the Pathogenesis of Parkinson's Disease., PMID:40244042
High Agreement Across Laboratories Between Different Alpha-Synuclein Seed Amplification Protocols., PMID:40237217
Exploring LRRK2-dependent Mechanisms in Parkinson's Disease Therapy., PMID:40231505
Co-occurrence of parkinson disease and multiple sclerosis - a critical note., PMID:40214766
The bridge-like lipid transport protein VPS13C/PARK23 mediates ER-lysosome contacts following lysosome damage., PMID:40211074
Transcriptome signatures of human neural stem cells derived from LRRK2 gene therapeutic cells., PMID:40210948
Leucine-Rich Repeat Kinase 2 Promotes Disintegration of Retinal Pigment Epithelial Cell: Implication in the Pathogenesis of Dry Age-Related Macular Degeneration., PMID:40204187
Plasma and urinary metabolomic signatures differentiate genetic and idiopathic Parkinson's disease., PMID:40204143
Integration of network pharmacology and experimental validation to explore the pharmacological mechanism of andrographolide against asthma., PMID:40198539
Precision Medicine in Parkinson's Disease., PMID:40185526
Genetic variants associated with idiopathic Parkinson's disease in Latin America: A systematic review., PMID:40178685
PPM1M, a LRRK2-counteracting, phosphoRab12-preferring phosphatase with potential link to Parkinson's disease., PMID:40166354
Enhancing anti-CD3 mAb-mediated diabetes remission in autoimmune diabetes through regulation of dynamin-related protein 1(Drp1)-mediated mitochondrial dynamics in exhausted CD8+T-cell subpopulations., PMID:40165248
Next Generation Sequencing Analysis in Patients Affected by Parkinson's Disease and Correlation Between Genotype and Phenotype in Selected Clinical Cases., PMID:40141040
LRRK2 reduces the sensitivity to TKI and PD-1 blockade in ccRCC via activating LPCAT1., PMID:40121376
Viral mediated α-synuclein overexpression results in greater transgene levels and α-synuclein overload in mice bearing kinase dead mutation of LRRK2., PMID:40121347
For research use only. Not for human or drug use.
